Inspire’s Diquafosol Is “Approvable” For Dry Eye; FDA Requests Efficacy Data
Executive Summary
Inspire Pharmaceuticals hopes that supplemental Phase III data on the dry eye agent diquafosol (INS 365) will help address efficacy questions raised by FDA in a Dec. 19 "approvable" letter
You may also be interested in...
Inspire hopes for diquafosol approval in 2005
Inspire Pharmaceuticals says it hopes to gain approval for the dry eye agent diquafosol in 2005 pending completion of an additional clinical study required by FDA. The agency requested the study during a Jan. 29 meeting concerning a Dec. 19 "approvable" letter (1"The Pink Sheet" Jan. 5, 2004, p. 29)...
Inspire hopes for diquafosol approval in 2005
Inspire Pharmaceuticals says it hopes to gain approval for the dry eye agent diquafosol in 2005 pending completion of an additional clinical study required by FDA. The agency requested the study during a Jan. 29 meeting concerning a Dec. 19 "approvable" letter (1"The Pink Sheet" Jan. 5, 2004, p. 29)...
Allergan Restasis Launch Set For April Following Approval Of Dry Eye Drug
Allergan's chronic dry eye disease agent Restasis (cyclosporine ophthalmic emulsion 0.5%) will be available in early April, following FDA approval Dec. 23